Animal studies revealed that three daily intraperitoneal doses of a soluble analogue of STF-31 effectively reduce the growth of tumors of VHL-deficient renal cell carcinoma cells in these mice. Here, VHL is linked to hereditary clear cell renal cell carcinoma.